載入中
NASDAQHealthcareBiotechnology
最新資料
US$2.515
−US$0.375 · -12.98%
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
收盤時
US$2.515
−US$0.375 · -12.98%
盤後
US$2.76
+US$0.245 · +9.74%
10月13日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
日內區間
目前US$2.515
52週區間
目前US$2.515
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 575.95萬 USD | 1189.86萬 USD | 1270.53萬 USD | 1464.91萬 USD | 3203.89萬 USD |
| 銷售、一般及管理費用 | 934.35萬 USD | 994.98萬 USD | 1041.43萬 USD | 1058.22萬 USD | 1332.67萬 USD |
| 營業費用 | 1510.3萬 USD | 2184.84萬 USD | 2311.96萬 USD | 2523.13萬 USD | 4536.57萬 USD |
| 利息收入 | 94.81萬 USD | 127.2萬 USD | 143.7萬 USD | 55.69萬 USD | 1.65萬 USD |
| 利息支出 | — | 456.2萬 USD | 828.3萬 USD | 740.7萬 USD | 632.7萬 USD |
| 折舊和攤銷 | 5442 USD | 2.25萬 USD | 3.1萬 USD | 8513 USD | 10.18萬 USD |
| 營業利益 | −1510.3萬 USD | −2184.84萬 USD | −2311.96萬 USD | −2523.13萬 USD | −4536.57萬 USD |
| 淨利 | −2.93億 USD | 143.89萬 USD | −3000.54萬 USD | −3210.87萬 USD | −4990.6萬 USD |
公司資料更新於 2026年10月14日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$10.00
上漲空間 297.61%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2022年6月21日 | 1:8 | — | — |
已生效 2022年6月21日
1:8
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI641.34萬0.00%2.3兆 USD0.03%US$381.32-0.07%
Vanguard Extended Market ETFVXF242.63萬0.00%954億 USD0.05%US$232.54-0.42%
iShares Russell 2000 ETFIWM237.75萬0.00%777.48億 USD0.19%US$276.7-0.43%
Vanguard Russell 2000 ETFVTWO89.54萬0.00%180億 USD0.06%US$111.77-0.45%
iShares Russell 2000 Growth ETFIWO63.39萬0.00%137.9億 USD0.24%US$351.1-0.74%
iShares Micro-Cap ETFIWC33.13萬0.03%13.07億 USD0.60%US$179.6-1.13%
iShares Russell 2000 Value ETFIWN26.62萬—137.52億 USD0.24%US$210.99-0.05%
Vanguard Russell 2000 Growth ETFVTWG11.61萬0.01%17億 USD0.06%US$256.21-0.80%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCiShares Russell 2000 Value ETFIWNVanguard Russell 2000 Growth ETFVTWGAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
